AVBP SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates ArriVent BioPharma, Inc. For Possible Securities Law Violations
NEW YORK CITY, NY / ACCESS Newswire / October 6, 2026 /Levi & Korsinsky notifies investors that it has commenced an investigation into ArriVent BioPharma, Inc. ("ArriVent BioPharma, Inc.") (NASDAQ:AVBP) concerning potential violations of the federal securities laws.
ArriVent BioPharma, Inc. shareholders lost money on October 6, 2026, when the stock fell sharply after the Company announced that its global Phase 3 FURVENT trial of firmonertinib failed to meet its primary endpoint of progression-free survival by blinded independent central review in previously untreated patients with EGFR exon 20 insertion--mutated non-small-cell lung cancer. On this news, the Company 's shares collapsed roughly 50%--63% during the session, reaching a 52-week low near $12.09. Previously, on November 10, 2025, the Company filed an exhibit to Form 8-K representing that "An interim analysis for this study has not been performed and there is no plan to perform such analysis given the expected timing of top-line data." Later, on May 11, 2026, the Company filed a Form 424B5 prospectus supporting an at-the-market offering of up to $250,000,000, which described the Company as actively conducting the pivotal Phase 3 trial and seeking to support firmonertinib. The investigation concerns whether ArriVent BioPharma, Inc. adequately disclosed the clinical trial 's progress and the timing of any negative efficacy data ahead of the October 6, 2026 announcement.
If you suffered a loss on your ArriVent BioPharma, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY:Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services ' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
SOURCE:Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.
